Bracco is an international Group active in the healthcare sector through Bracco Imaging (Diagnostic Imaging), Pharma (prescription and over the counter drugs), Acist Medical Systems (medical devices and advanced imaging agents injection systems based in Minneapolis, USA), and the Centro Diagnostico Italiano diagnostic clinic in Milan. It has more than 3200 employees and annual total consolidated revenues of over 1,1 billion euros, of which 75% from international sales, and it is present worldwide. In the Research and Innovation area, the company invests approximately 10% of reference turnover in the imaging diagnostics and medical devices sectors and has a portfolio comprising over 1,500 patents.
Originally established as a pharmaceutical company in 1927, over the years Bracco has intensified its commitment to innovative specialist research in imaging agents for diagnostic medicine. A key breakthrough came in the 1970’s with the development of the Iopamidol, the first ready-to-use non-ionic contrast agent. In the wake of this success, at the end of the 1980’s the Group launched a program for international expansion, notably in the USA, now Bracco Imaging’s primary market.
Its subsidiary Bracco Imaging is one of the world’s leading companies in the Diagnostic Imaging.
Bracco Imaging offers a products, injectors and solutions portfolio for all diagnostic applications :X-Ray Imaging (including Computed Tomography-CT), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound, and Nuclear Medicine. Imaging agents are pharmaceutical products aimed at supporting diagnosis and monitoring of various pathologies.
The Company operates in over 100 markets worldwide, either directly or indirectly, through subsidiaries, joint-ventures, licenses and distribution partnership agreements. With an ongoing research covering all key modalities, Bracco Imaging has a strong presence in key geographies: North America through Bracco Diagnostics Inc. USA headquartered in Princeton, NJ, and with an affiliate in Montreal (Canada); Europe, with offices in all major countries; Japan, where it operates through a licensing agreement with Bayer Schering and a controlled joint-venture BRACCO-EISAI Co., Ltd. The Company also operates in South America, South Korea and China through its 70% controlled joint-venture, Bracco Sine Pharmaceutical Corp. Ltd.
Bracco Imaging is an innovative R&I player with an efficient process oriented approach and a track record of innovation in the Diagnostic Imaging industry. R&D activities are managed in the Research Centers located in Colleretto Giacosa (Italy) and Geneva and Lousanne (Switzerland), Minneapolis and the Sillicon Valley (USA). Each Research Center possesses highly specialized expertise in diverse Diagnostic Imaging modalities and techniques. Additional development expertise and support functions exist in Milan, Beijing, Konstanz (Germany), Montreal (Canada) and Tokyo (Japan). Bracco Imaging also has a number of research collaboration agreements with prestigious University Departments, Hospital-based Research Centers and Biotech Companies in various parts of the world.
Operational investments have been made by Bracco Imaging in order to achieve top quality and compliances with a sustainable ecology friendly production. Manufacturing activities are located in Italy (Ceriano Laghetto, Torviscosa and Ivrea), Canada (Montreal), Switzerland (Geneva), Japan (Saitama), China (Shanghai) and Germany (Singen).
The Bracco Diagnostic Imaging offer is completed by several medical devices and advanced administration systems for contrast imaging products in the fields of cardiology and radiology, developed by Acist Medical Systems. The company, which was acquired by the Bracco Group in 2001, has its corporate headquarters, manufacture and R&D facilities in Minneapolis, Minnesota (USA), with regional offices in Europe and Asia. Its advanced systems are used in over 40 countries in the most world-renowned centers. More than 10 million people around the world have had cardiovascular angiographic procedures using an ACIST system.
In Italy, Bracco Group is a key player in many strategically important therapeutic fields, including gastroenterology, neurology, endocrinology and cardio-vascular pathology, where it markets own-brand drugs or pharmaceuticals under license. Bracco SpA is present in the territory through a network of 240 pharmaceutical representatives, supported by a diffused sales organization. This network has acquired a high reputation amongst pharmacists.
The Bracco brand is widely known in Italy for its over-the-counter products, both pharmaceutical and dietetics, and nutraceutical products. The product range includes Cebion, Xamamina, Euclorina, the Alfa eye-drops product line and Friliver.
Another important area of activity of the Bracco Group regards the healthcare services provided by the Centro Diagnostico Italiano, a polyclinic based in Milan. With 21 satellite units in the city and in Lombardy, CDI offers different services of prevention, diagnosis, rehabilitation and personalized treatment, with a focus on radio-surgery and on day-surgery. With a 30 years experience, it offers a wide range of services for an amount per year of 150.000 diagnostic procedures in 50 clinical specializations and 4 million analysis for 500 types of exams. Equipped with the very latest technological systems (such as the Cyberknife radiosurgery robot and the Ikonyscope microscope for oncologic diagnostics), the CDI is an accredited body of the Joint Commission International.
Since its foundation Bracco is a socially responsible company in each area of activity – in business as in every other context . The company is strongly committed to social, educational, environmental and cultural improvement and in the promotion of Gender Equality.
The Bracco Group
exists since 1927,
when Elio Bracco
founded the Italian
E. Merck company
The Bracco Group,
through its subsidiary
the world both directly
The Bracco Group
resources in the Research
and Development field.